Annual Grant Award Dollars
| Investigator | Title | Sponsor | ID | Dates | Amount |
| Mark Althoff | Scribble in hematopoietic stem cell activity | National Institutes of Health (NIH) | F31HL132468 | 4/1/2018 - 3/31/2020 | $37,956 |
| Paul Andreassen, PHD | A Novel and Rapid System to Classify BRCA2 Missense and Other Variants in Ovarian Cancer | National Institutes of Health (NIH) | W81XWH1810269 | 6/15/2019 - 6/14/2020 | $216,965 |
| Laura Barreyro, PHD | Training grant | University of Cincinnati (National Institutes of Health (NIH)) | 1013581 | 9/30/2016 - 9/29/2017 | $12,780 |
| Laura Barreyro, PHD | Targeting UBE2N in Myelodysplastic Syndromes and Acute Myeloid Leukemia | American Society of Hematology | ASH, Barreyro, Laura | 7/1/2018 - 6/30/2019 | $50,000 |
| Kalen P Berry, PHD | Training grant | University of Cincinnati (National Institutes of Health (NIH)) | 1014415 | 9/1/2018 - 8/31/2019 | $48,432 |
| Jose Cancelas-Perez Carolyn M Lutzko |
G-CSF in Human Severe Congenital Neutropenia | National Institutes of Health (NIH) | R01GM110628 | 7/1/2018 - 12/31/2019 | $308,100 |
| Jose Cancelas-Perez | Disseminating Curative Biological Therapies for Rare Ped | Children's Hospital Boston (National Institutes of Health (NIH)) | GENFD0001506981 | 7/1/2018 - 8/31/2019 | $160,724 |
| Timothy M Chlon, PHD | Pathogenesis of Inherited Myelodysplastic Syndromes | National Institutes of Health (NIH) | F32HL143993 | 7/1/2018 - 6/30/2019 | $67,985 |
| Ashley E Cochran, PHD | Environmental Carcinogenesis and Mutagenesis | University of Cincinnati (National Institutes of Health (NIH)) | 1014229 | 7/1/2018 - 6/30/2019 | $35,552 |
| Ashley E Cochran, PHD | Unrestricted A20 activity in acute myeloid leukemia | National Institutes of Health (NIH) | F32CA232402 | 3/1/2019 - 11/30/2019 | $70,430 |
| Marie-Dominique Filippi, PHD | Molecular Regulation of Neutrophil Transcellular Migration | National Institutes of Health (NIH) | R01GM112792 | 7/1/2018 - 6/30/2020 | $308,100 |
| Marie-Dominique Filippi, PHD Punam Malik, MD |
Regulation of hematopoietic stem cell self-renewal by GT | National Institutes of Health (NIH) | R01DK102890 | 7/1/2018 - 6/30/2019 | $416,320 |
| Matthew Flick, PHD | Novel anti-fibrotic mechanisms in chemical-induced liver | Michigan State University (National Institutes of Health (NIH)) | RC105176CHMC | 7/1/2018 - 5/10/2019 | $36,139 |
| Matthew Flick, PHD | Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated Thrombosis | National Institutes of Health (NIH) | U01HL143403 | 7/1/2018 - 6/30/2019 | $818,452 |
| Matthew Flick, PHD | Fibrin(ogen) control of metabolic inflammation and obesity | National Institutes of Health (NIH) | R01DK112778 | 12/20/2018 - 11/30/2019 | $404,907 |
| FuKun Guo, PHD | Targeting of Cdc42 as a cancer immunotherapy for pediatric medulloblastoma | Cancer Free Kids | cfk | 7/1/2018 - 6/30/2020 | $50,000 |
| FuKun Guo, PHD | Pharmacological targeting Cdc42 as an immunotherapy for pancreatic cancer | University of Cincinnati Cancer Center | 011742-002 | 9/1/2018 - 8/31/2019 | $47,500 |
| FuKun Guo, PHD | RhoA in T Cell-mediated Airway Inflammation | National Institutes of Health (NIH) | R56HL141499 | 9/15/2018 - 8/31/2019 | $397,500 |
| Robert Francis Hennigan, PHD | Identification of Novel Signaling Pathways in NF2 | National Institutes of Health (NIH) | W81XWH1710152 | 7/1/2018 - 6/30/2019 | $78,000 |
| Cindy LF Hochstetler | Impact of abnormal bone marrow endothelial niche on hematopoiesis | National Institutes of Health (NIH) | F31HL136229 | 3/1/2018 - 2/29/2020 | $39,096 |
| Leah J Kershner | Training grant | University of Cincinnati (National Institutes of Health (NIH)) | 1014415 | 9/1/2018 - 8/31/2019 | $48,432 |
| Kakajan Komurov, PHD | Exploiting proteotoxic stress in therapy-refractory HER2 | National Institutes of Health (NIH) | R01CA193549 | 5/1/2019 - 4/30/2020 | $346,144 |
| Kakajan Komurov, PHD | The role of transcription elongation defects in immunotherapy resistance in cancers | National Institutes of Health (NIH) | R01CA234038 | 5/15/2019 - 4/30/2020 | $446,129 |
| Qing Richard Lu, PHD | Molecular Mechanisms of Oligodendrocyte Differentiation | National Institutes of Health (NIH) | R01NS072427 | 9/1/2018 - 8/31/2019 | $466,702 |
| Qing Richard Lu, PHD | Molecular and signaling mechanisms of peripheral nerve sheath tumorigenesis | National Institutes of Health (NIH) | R37NS096359 | 9/1/2018 - 8/31/2019 | $529,965 |
| Qing Richard Lu, PHD | Chromatin remodeling control of myelination and remyelination | National Institutes of Health (NIH) | R01NS075243 | 7/1/2018 - 6/30/2019 | $446,256 |
| Daniel Lucas, PHD | Cellular crosstalk in the hematopoietic microenvironment | National Institutes of Health (NIH) | R01HL136529 | 5/1/2019 - 4/30/2020 | $396,133 |
| Punam Malik, MD | GMP Vector Production for Gene Therapy for Sickle Cell Disease | Cleveland Clin Lerner Col of Med of CWRU (National Institutes of Health (NIH)) | 987-SUB | 5/1/2018 - 4/30/2019 | $194,250 |
| Punam Malik, MD | Preclinical efficacy study for the modified gamma globin lentivirus vector flanked by the foamy virus insulator | Aruvant Sciences, Inc | Malik, P., Aruvant | 3/25/2019 - 3/24/2021 | $1,531,368 |
| Katelyn Melgar | Novel mechanisms and therapeutic strategies of refractory leukemia | National Institutes of Health (NIH) | F31CA217140 | 5/1/2019 - 4/30/2020 | $37,696 |
| James Mulloy, PHD | The role of Hedgehog Signaling in gastric tissue repair | University of Cincinnati (National Institutes of Health (NIH)) | 010446-009 | 5/1/2018 - 4/30/2019 | $43,234 |
| James Mulloy, PHD | Instructive role of MLL fusion proteins in lineage determination and leukemogenesis | The University of Chicago (National Institutes of Health (NIH)) | FP064422-01 | 3/1/2018 - 2/28/2019 | $318,850 |
| James Mulloy, PHD | Instructive role of MLL fusion proteins in lineage determination and leukemogenesis | The University of Chicago (National Institutes of Health (NIH)) | FP064422-01 | 3/1/2019 - 2/29/2020 | $343,650 |
| James Mulloy, PHD | Instructive role of MLL fusion proteins in lineage determination and leukemogenesis | The University of Chicago (National Institutes of Health (NIH)) | FP064422-01 | 3/1/2018 - 2/28/2019 | $35,398 |
| James Mulloy, PHD | Molecular and Cellular Mechanisms of Chronic Myelomonocy | University of Wisconsin-Madison (National Institutes of Health (NIH)) | 731K430 | 3/1/2018 - 2/28/2019 | $39,000 |
| James Mulloy, PHD | Leukemia stem cell polarity and differentiation therapy | National Institutes of Health (NIH) | R01CA204895 | 8/1/2018 - 7/31/2019 | $442,805 |
| Tomoya Muto, PHD | A Novel Tumor Suppressor Function of the TRAF6 Ubiquitin Ligase in Myeloid Malignancies | The Leukemia and Lymphoma Society | 338819 | 7/1/2018 - 6/30/2019 | $66,999 |
| Nicolas Nassar, PHD | Targeted Inhibition in Triple Negative Breast Cancer | National Institutes of Health (NIH) | R21CA229930 | 7/24/2018 - 6/30/2019 | $172,913 |
| Nicolas Nassar, PHD | Inhibitors of RAC Activation in Leukemia | University of Cincinnati | CCC Pilot | 8/1/2018 - 12/31/2019 | $60,000 |
| Haixia Niu, PHD | Identification of RXR signaling in bone marrow adipocytes and B precursor acute lymphoblastic leukemia | The Ohio State University Research Fnd | 277306 | 6/1/2018 - 5/31/2019 | $64,833 |
| Qishen Pang, PHD | FA DDR Pathway in Germline Integrity | National Institutes of Health (NIH) | R01HD089932 | 4/1/2018 - 3/31/2019 | $329,925 |
| Qishen Pang, PHD | FA DDR Pathway in Germline Integrity | National Institutes of Health (NIH) | R01HD089932 | 4/1/2019 - 3/31/2020 | $329,925 |
| Annmarie Ramkissoon | Innovative Targeting of Chemo-Resistant Pediatric MPNST | Cancer Free Kids | cfk | 7/1/2018 - 6/30/2020 | $48,000 |
| Nancy Ratner, PHD | Disordered Regulation of Wnt/?-catenin Signaling in MPNS | University of Minnesota (National Institutes of Health (NIH)) | 48106 | 7/1/2018 - 6/30/2019 | $274,835 |
| Nancy Ratner, PHD | Brain Dysfunction in Neurofibromatosis | National Institutes of Health (NIH) | R01NS091037 | 4/1/2019 - 3/31/2020 | $309,792 |
| Nancy Ratner, PHD | Targeting Tumors with NF1 loss | Trustees of Dartmouth (National Institutes of Health (NIH)) | R836 | 8/1/2018 - 7/31/2019 | $108,311 |
| Nancy Ratner, PHD | An innovative NF1 drug discovery pipeline for preclinical development of novel drugs quickly, safely, and effectively | The Children's Tumor Foundation (The Children's Tumor Foundation) | CTF | 7/1/2018 - 11/30/2019 | $75,891 |
| Nancy Ratner, PHD | Schwann cell interactions with the neurofibroma microenvironment | National Institutes of Health (NIH) | W81XWH1710289 | 7/1/2018 - 6/30/2019 | $299,001 |
| Nancy Ratner, PHD | Mitogenic Activities in Neurofibromatosis | National Institutes of Health (NIH) | R01NS028440 | 7/1/2018 - 6/30/2019 | $445,976 |
| Nancy Ratner, PHD | Ras Proteins in Nerve Tumorigensis | National Institutes of Health (NIH) | R37NS083580 | 8/1/2018 - 4/30/2020 | $795,000 |
| Damien Reynaud, PHD | Normal and Pathological Hematopoietic Stem Cells in Obesity | National Institutes of Health (NIH) | R01HL141418 | 4/1/2019 - 3/31/2020 | $397,500 |
| Mathieu Sertorio, PHD | Improving the outcome of aggressive childhood lymphomas by combining proton precision therapy with mitochondrial targeting | Cancer Free Kids | cfk | 7/1/2018 - 6/30/2020 | $50,000 |
| Molly Smith | Aberrant Ubiquitin Editing in the Pathogenesis of Myeloid Malignancies | National Institutes of Health (NIH) | F31HL132420 | 9/1/2018 - 8/31/2019 | $37,505 |
| Daniel T. Starczynowski, PHD | Investigating genetic and molecular determinants of myelodysplastic syndromes | The Leukemia and Lymphoma Society | 133416 | 7/1/2018 - 6/30/2019 | $110,001 |
| Daniel T. Starczynowski, PHD | Rational design of dual IRAK1/4 inhibitors as a new therapy for MDS | The Leukemia and Lymphoma Society | 651117 | 10/1/2018 - 9/30/2019 | $200,000 |
| Daniel T. Starczynowski, PHD | Decoding innate immune signaling in normal and myelodysplastic hematopoiesis | National Institutes of Health (NIH) | R35HL135787 | 1/1/2019 - 12/31/2019 | $788,750 |
| Daniel T. Starczynowski, PHD | Targeting IRAK1/4 in Myelodysplastic Syndromes | National Institutes of Health (NIH) | R01DK113639 | 6/1/2019 - 5/31/2020 | $481,139 |
| Ronald R Waclaw, PHD | Signaling pathways regulating oligodendrocyte development and function | National Institutes of Health (NIH) | R01NS088529 | 3/1/2019 - 2/29/2020 | $341,250 |
| Ronald R Waclaw, PHD Kenneth J Campbell, PHD |
Molecular Mechanisms Controlling Formation of Basal Ganglia Circuitry | National Institutes of Health (NIH) | 2R01MH090740 | 7/11/2018 - 4/30/2020 | $601,332 |
| Jianqiang Wu, MD | miR-155 and RUNX function in neurofibroma tumorigenesis | National Institutes of Health (NIH) | R01NS097233 | 7/1/2018 - 6/30/2019 | $341,250 |
| Lai Man Wu, PHD | Molecular and signaling mechanisms of malignant transformation in peripheral nerve sheath tumors | The Children's Tumor Foundation | 201701014 | 7/3/2018 - 7/2/2019 | $53,999 |
| Lai Man Wu, PHD | Single-cell transcriptomics and epigenomics to identify tumor-microenvironment Interactions for targeted treatment of MPNST | Sarcoma Foundation of America | Wu, SFA | 6/1/2019 - 5/31/2020 | $50,000 |
| Mark Wunderlich | Therapeutic insights through patient derived leukemia xe | National Institutes of Health (NIH) | R50CA211404 | 9/1/2018 - 8/31/2019 | $172,232 |
| Mei Xin, PHD | Hippo Signaling in Heart Development and Repair | National Institutes of Health (NIH) | R01HL132211 | 4/1/2018 - 3/31/2020 | $397,800 |
| Mei Xin, PHD | Targeting the Hippo signaling at the Blood-brain barrier for therapy of ischemic stroke | University of Cincinnati (National Institutes of Health (NIH)) | 011818-002 | 9/30/2018 - 7/31/2019 | $99,793 |
| Chuntao Zhao, PHD | Combination of Target Therapy and Radiation for Curing Medulloblastoma in Pre-Clinical Models | Cancer Free Kids | CFK | 7/1/2018 - 6/30/2020 | $50,000 |
| Yi Zheng, PHD | Targeting Cdc42 for bone marrow transplant therapies | National Institutes of Health (NIH) | R01CA193350 | 5/1/2019 - 4/30/2020 | $346,144 |
| Yi Zheng, PHD | Cdc42, hematopoietic stem cell polarity, and cell fate | National Institutes of Health (NIH) | R01DK104814 | 12/1/2018 - 11/30/2019 | $496,716 |
| Yi Zheng, PHD | Targeting TET1 signaling to treat acute myeloid leukemia | City of Hope (National Institutes of Health (NIH)) | 60677.2004668.669301 | 1/1/2019 - 12/31/2019 | $66,581 |
| Yi Zheng, PHD Jose A Cancelas |
Small molecules targeting RhoA for platelet cold storage in cancer care | National Institutes of Health (NIH) | R01HL147536 | 4/1/2019 - 2/29/2020 | $635,494 |
| Current Year Direct | $18,369,837 | ||||
Annual Industry Award Dollars
| Investigator | Industry Sponsor | Amount |
| Nancy Ratner, PHD | Boehringer Ingelheim Pharmaceuticals | $358,101 |
| Nancy Ratner, PHD | Revolution Medicines Inc. | $124,031 |
| Punam Malik, MD | Calimmune, Inc. | $554,733 |
| Total Annual Industry Award Dollars | $1,036,865 | |
